Novartis Pharmaceuticals and Novartis Oncology, forming together the Innovative Medicines Division, are the two newly created business units of Swiss giant Novartis. The leader of each business will join the Executive Committee of Novartis (ECN) starting from July 1, 2016. Paul Hudson will be appointed CEO, Novartis Pharmaceuticals and Bruno Strigini will become CEO, Novartis Oncology. Both will report directly to Joseph Jimenez, CEO of Novartis. The new structure reflects the integration of the oncology assets acquired from GSK.